RDY Stock - Dr. Reddy's Laboratories Limited
Unlock GoAI Insights for RDY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $325.54B | $279.16B | $245.88B | $214.39B | $2.56B |
| Gross Profit | $190.43B | $163.61B | $139.34B | $113.84B | $1.30B |
| Gross Margin | 58.5% | 58.6% | 56.7% | 53.1% | 50.8% |
| Operating Income | $71.84B | $67.73B | $57.14B | $29.48B | $431.44M |
| Net Income | $56.54B | $55.68B | $45.07B | $23.57B | $232.21M |
| Net Margin | 17.4% | 19.9% | 18.3% | 11.0% | 9.1% |
| EPS | $67.85 | $66.80 | $54.29 | $28.42 | $20.79 |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 5th 2025 | HSBC Securities | Upgrade | Buy | $16.9 |
| December 19th 2024 | Nomura | Downgrade | Neutral | - |
| January 11th 2024 | Jefferies | Downgrade | Underperform | - |
| August 29th 2023 | HSBC Securities | Downgrade | Hold | - |
| May 18th 2023 | Bernstein | Downgrade | Market Perform | - |
| March 17th 2023 | BofA Securities | Upgrade | Buy | - |
| January 30th 2023 | JP Morgan | Initiation | Underweight | - |
| November 14th 2022 | Credit Suisse | Downgrade | Underperform | - |
Earnings History & Surprises
RDYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Jan 22, 2026 | $0.16 | — | — | — |
Q4 2025 | Oct 24, 2025 | $0.18 | $0.19 | +5.6% | ✓ BEAT |
Q3 2025 | Jul 23, 2025 | $0.18 | $0.20 | +11.1% | ✓ BEAT |
Q2 2025 | May 9, 2025 | $0.20 | $0.22 | +10.0% | ✓ BEAT |
Q1 2025 | Jan 29, 2025 | $0.19 | — | — | — |
Q4 2024 | Nov 5, 2024 | $0.04 | $0.04 | -9.8% | ✗ MISS |
Q3 2024 | Jul 27, 2024 | $0.22 | $0.20 | -9.1% | ✗ MISS |
Q2 2024 | Jun 12, 2024 | — | $0.20 | — | — |
Q2 2024 | May 7, 2024 | $0.17 | $0.19 | +11.8% | ✓ BEAT |
Q4 2023 | Oct 27, 2023 | $0.18 | $0.21 | +16.7% | ✓ BEAT |
Q3 2023 | Jul 26, 2023 | $0.14 | $0.21 | +50.0% | ✓ BEAT |
Q2 2023 | Jun 13, 2023 | — | $0.18 | — | — |
Q2 2023 | May 10, 2023 | $0.11 | $0.14 | +27.3% | ✓ BEAT |
Q4 2022 | Oct 28, 2022 | $0.12 | $0.16 | +33.3% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $0.12 | $0.18 | +50.0% | ✓ BEAT |
Q2 2022 | May 19, 2022 | $0.86 | $0.11 | -87.3% | ✗ MISS |
Q1 2022 | Jan 28, 2022 | $0.17 | $0.11 | -34.1% | ✗ MISS |
Q4 2021 | Oct 29, 2021 | — | $0.16 | — | — |
Q3 2021 | Jul 27, 2021 | $0.11 | $0.09 | -18.2% | ✗ MISS |
Latest News
Immutep shares are trading higher after the company and Dr. Reddy's announced that their respective wholly-owned subsidiaries have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China.
📈 PositiveImmutep And Dr. Reddy's Enter Collaboration And Exclusive Licensing Agreement For commercialization Of Eftilagimod Alfa In All Countries Outside North America, Europe, Japan And Greater China; Immutep To Receive $20M Upfront Payment And Milestones Up To $349.5M Plus Royalties
📈 PositiveDr. Reddy's Laboratories' Aurigene Oncology Unit Results From 1st Two Groups Of Phase 1 Clinical Study Of AUR112 Demonstrates Safety, Meaningful Clinical Activity With Objective Responses Observed Across Multiple Lymphoma Subtypes
📈 PositiveDr. Reddy's shares are trading lower after the company received a non-compliance notice for its semaglutide injection in Canada.
📉 NegativeDr Reddy's Laboratories Q2 EPS $0.19 Beats $0.18 Estimate, Sales $992.000M Beat $982.910M Estimate
📈 PositiveEsperion, Dr. Reddy's Laboratories Reach Patent Dispute Settlement; Dr. Reddy's Agrees Not To Market NEXLETOL Or NEXLIZET In US Before 2040
📈 PositiveExtrovis And Dr. Reddy's Launch Authorized Generic Of Carac Fluorouracil Cream 0.5%, In U.S. Market
📈 PositiveFrequently Asked Questions about RDY
What is RDY's current stock price?
What is the analyst price target for RDY?
What sector is Dr. Reddy's Laboratories Limited in?
What is RDY's market cap?
Does RDY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RDY for comparison